Prophylaxis glycopyrolate reduce cardiovascular effects from propofol and reduce salivary during change position in open urologic patients

Phase 4

Completed

• Conditions: ASA I- II elective nephrolithotomy and ureterolithotomy and nephrectomy surgery patients; Elective nephrolithotomy and ureterolithotomy and nephrectomy surgery patients

• Registration Number: TCTR20200910001
• Lead Sponsor: Sawanpracharak Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-08-31
• Study Start: 2020-09-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

ASA I-II Elective nephrolithotomy and ureterolithotomy and nephrectomy surgery patients

Exclusion Criteria

glaucoma, prostatic hypertrophy, hyperthyroid, cardiovascular disease, pulmonary disease, morbid obesity, renal or hepatic dysfunction, neuromuscular disease, premedication used in sugery day

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
efficacy of glycopyrrolate during induction and intubation phase for anesthesia cardiovascular effect,efficacy of glycopyrrolate during induction and intubation phase for anesthesia salivary volume

Secondary Outcome Measures

Name	Time	Method
cardiovascular effect during induction and intubation phase for anesthesia blood presure, heart rate